譽衡藥業(002437.SZ):控股股東及一致行動人減持期屆滿 累計減持1.99%股份
格隆匯4月7日丨譽衡藥業(002437.SZ)公佈,於2019年9月7日披露,公司控股股東譽衡集團及一致行動人譽衡國際、健康科技及其質權人自公告發布之日起15個交易日後的6個月內,可能通過集中競價交易方式減持公司股份將合計不超過4396.25萬股,不超過公司總股本的2%。
2020年4月7日,公司收到譽衡集團及一致行動人譽衡國際、健康科技的《告知函》,截至2020年4月5日,譽衡集團、譽衡國際、健康科技的本次減持計劃期限已屆滿,譽衡集團及譽衡國際合計減持4368.87萬股,減持比例1.99%。本次減持後譽衡集團合計持有股份37.39%,譽衡國際合計持有股份10.33%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.